“During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “We announced a strategic partnership with DCx Biotherapeutics to out-license our discovery platforms, and we are exploring a full range of strategic alternatives and partnerships across our portfolio. We are well-positioned from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to report initial data for both the LIONS and POLAR trials in the second half of this year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics
- Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide
- Repare Therapeutics Announces Leadership Changes in 2025
- Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue